{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T18:54:33Z","timestamp":1791053673685,"version":"4.1.0"},"reference-count":26,"publisher":"American Physiological Society","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["American Journal of Physiology-Gastrointestinal and Liver Physiology"],"published-print":{"date-parts":[[2008,1]]},"abstract":"<jats:p> Cannabinoid receptors (CB1 and CB2) and their endogenous ligands (endocannabinoids) have recently emerged as novel mediators of liver diseases. Endogenous activation of CB1 receptors promotes nonalcoholic fatty liver disease (NAFLD) and progression of liver fibrosis associated with chronic liver injury; in addition, CB1 receptors contribute to the pathogenesis of portal hypertension and cirrhotic cardiomyopathy. CB2 receptor-dependent effects are also increasingly characterized, including antifibrogenic effects and regulation of liver inflammation during ischemia-reperfusion and NAFLD. It is likely that the next few years will allow us to delineate whether molecules targeting CB1 and CB2 receptors are useful therapeutic agents for the treatment of chronic liver diseases. <\/jats:p>","DOI":"10.1152\/ajpgi.00467.2007","type":"journal-article","created":{"date-parts":[[2007,11,2]],"date-time":"2007-11-02T00:59:25Z","timestamp":1193965165000},"page":"G9-G12","source":"Crossref","is-referenced-by-count":89,"title":["Endocannabinoids and Liver Disease. I. Endocannabinoids and their receptors in the liver"],"prefix":"10.1152","volume":"294","author":[{"given":"A.","family":"Mallat","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Lotersztajn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"24","reference":[{"key":"R1","doi-asserted-by":"publisher","DOI":"10.1038\/89953"},{"key":"R2","doi-asserted-by":"publisher","DOI":"10.1096\/fj.06-7451com"},{"key":"R3","unstructured":"Deveaux V, Ichigotani Y, Teixeira-Clerc F, Manin S, Tran-Van-Nhieu J, Karsak M, Zimmer A, Mallat A, Lotersztajn S. CB2 receptor antagonism reduces diet-induced obesity, insulin resistance and hepatic steatosis. Hepatology 46 Suppl: 308A, 2007."},{"key":"R4","doi-asserted-by":"publisher","DOI":"10.1002\/hep.21641"},{"key":"R5","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjp.0706331"},{"key":"R6","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.94.6.2238"},{"key":"R7","doi-asserted-by":"publisher","DOI":"10.1002\/hep.20733"},{"key":"R8","unstructured":"Hezode C, Zafrani ES, Roudot-Thoraval F, Costentin C, Hessami A, Bouvier-Alias M, Medkour F, Pawlotsky JM, Lotersztajn S, Mallat A. Daily cannabis use, a novel risk factor of steatosis severity in patients with chronic hepatitis C. Gastroenterology. In Press."},{"key":"R9","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2004.12.050"},{"key":"R10","doi-asserted-by":"publisher","DOI":"10.1038\/nri1602"},{"key":"R11","doi-asserted-by":"publisher","DOI":"10.1016\/S0014-5793(98)00581-X"},{"key":"R12","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.pharmtox.45.120403.095906"},{"key":"R13","unstructured":"Lotersztajn S, Teixeira-Clerc F, Julien B, Deveaux V, Ichigotani Y, Manin S, Tran-Van-Nhieu J, Karsak M, Zimmer A, Mallat A. CB2 receptors as new therapeutic targets during liver diseases. Br J Pharmacol. In Press."},{"key":"R14","unstructured":"Mallat A, Lotersztajn S. Endocannabinoids as novel mediators of liver diseases. J Endocrinol Invest 29: 58\u201365, 2006."},{"key":"R15","doi-asserted-by":"publisher","DOI":"10.1517\/14728222.11.3.403"},{"key":"R16","doi-asserted-by":"publisher","DOI":"10.1016\/j.tem.2006.11.006"},{"key":"R17","doi-asserted-by":"publisher","DOI":"10.1038\/346561a0"},{"key":"R18","doi-asserted-by":"publisher","DOI":"10.1111\/j.1478-3231.2006.01401.x"},{"key":"R19","doi-asserted-by":"publisher","DOI":"10.1038\/365061a0"},{"key":"R20","doi-asserted-by":"publisher","DOI":"10.1172\/JCI200523057"},{"key":"R21","doi-asserted-by":"publisher","DOI":"10.1124\/pr.58.3.2"},{"key":"R22","doi-asserted-by":"publisher","DOI":"10.1053\/gast.2002.30305"},{"key":"R23","unstructured":"Ryberg E, Larsson N, Sjogren S, Hjorth S, Hermansson NO, Leonova J, Elebring T, Nilsson K, Drmota T, Greasley PJ. The orphan receptor GPR55 is a novel cannabinoid receptor. Br J Pharmacol. In Press."},{"key":"R24","doi-asserted-by":"publisher","DOI":"10.1096\/fj.06-7717com"},{"key":"R25","doi-asserted-by":"publisher","DOI":"10.1038\/nm1421"},{"key":"R26","doi-asserted-by":"publisher","DOI":"10.1016\/j.cancergencyto.2006.06.014"}],"container-title":["American Journal of Physiology-Gastrointestinal and Liver Physiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.physiology.org\/doi\/pdf\/10.1152\/ajpgi.00467.2007","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,9]],"date-time":"2019-09-09T02:15:31Z","timestamp":1567995331000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.physiology.org\/doi\/10.1152\/ajpgi.00467.2007"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,1]]},"references-count":26,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2008,1]]}},"alternative-id":["10.1152\/ajpgi.00467.2007"],"URL":"https:\/\/doi.org\/10.1152\/ajpgi.00467.2007","relation":{},"ISSN":["0193-1857","1522-1547"],"issn-type":[{"value":"0193-1857","type":"print"},{"value":"1522-1547","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,1]]}}}